Clean Science and Technology (CLEAN) Q4 24/25 earnings summary

Executive summary

• Achieved record sales volumes across key products in FY 2025, driven by strong R&D, new product launches, and global expansion, with 64% of revenues from exports and a diversified portfolio.

• Maintained a debt-free balance sheet, robust corporate governance, and strong cash position to fund ongoing capex.

• Audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, were approved, with a final dividend of ₹4 per share recommended, subject to shareholder approval.

• Statutory auditors issued an unmodified opinion on both standalone and consolidated results for FY25.

Financial highlights

• Consolidated revenue for FY2025 rose 22% year-over-year to ₹967 crore; Q4 FY2025 revenue up 16% year-over-year to ₹264 crore.

• EBITDA for FY2025 increased 17% year-over-year to ₹388 crore, with EBITDA margin at 40.8%.

• PAT for FY2025 grew 8% year-over-year to ₹264 crore; Q4 FY2025 PAT up 6% year-over-year to ₹74 crore.

• Full-year HALS sales volume reached 1,900 tons, generating INR 80 crore in revenue.

• Performance chemicals contributed 69% of revenue, pharma and agro 19%, FMCG 12%.

Outlook and guidance

• Targeting 4,500 tons of HALS sales in FY 2026, with revenue expected to reach INR 210 crore.

• Full ramp-up of HALS capacity (10,000 tons) anticipated by FY 2028, with peak sales potential of INR 560–580 crore at current realizations.

• Two new performance chemical plants to be commercialized in August 2025 and February 2026, each with 10,000-ton capacity.

• FY 2026 consolidated revenue growth expected at 18–20%, with EBITDA margin guidance of ~40%.

• Capex of ~₹225 crore in FY2025, primarily for investment in Clean Fino Chem Ltd. and new performance chemical plants.